BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) will report its first-quarter 2024 financial results on May 6, 2024. The Company will host a conference call and webcast to discuss the results and provide a corporate update for investors, financial analysts, and the general public.

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. 

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at https://biontech.com/. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

 

FAQ

When will BioNTech report its first-quarter 2024 financial results?

BioNTech will report its first-quarter 2024 financial results on May 6, 2024.

What is the ticker symbol for BioNTech?

The ticker symbol for BioNTech is BNTX.

How can investors access the conference call and webcast for BioNTech's financial results?

Investors can access the live conference call via telephone by registering in advance and accessing the webcast through the Company's website.

Where can participants find the slide presentation and audio of the webcast?

The slide presentation and audio of the webcast will be available on the 'Events & Presentations' page in the Investor Relations section of BioNTech's website.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available shortly after the call and archived on BioNTech's website for 30 days following the call.